Sequential Infusion of CD19 and BCMA Chimeric Antigen Receptor T Cells to Improve Alloimmune-mediated Platelet Transfusion Refractoriness in Patients With Acute Leukemia in Complete Remission
Latest Information Update: 29 May 2025
At a glance
- Drugs Anti-BCMA-chimeric-antigen-receptor-T-cell-therapy-Shanghai-Unicar-Therapy-Bio-medicine-Technology (Primary) ; Anti-CD19 chimeric antigen receptor T cell therapy Shanghai Unicar Therapy Bio-medicine Technology (Primary)
- Indications Leukaemia
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 29 May 2025 New trial record